title: Antinociception and delta-1 opioid receptors in the rat spinal cord: studies with intrathecal 7-benzylidenenaltrexone.
abstract: As part of the continuing investigation of the role of spinal delta opioid receptors in antinociception, this study characterized the ability of 7-benzylidenenaltrexone (BNTX), a selective delta-1 opioid receptor antagonist, to antagonize the antinociception produced in the rat by intrathecal (i.t.) administration of the respective delta-1 and delta-2 opioid receptor agonists, DPDPE and [D-Ala2, Glu4]deltorphin (DELT), or the mu receptor agonist DAMGO. In the tail flick test, 10-min pretreatment with 1 microgram of BNTX, increased the ED50 value of DPDPE from 27.5 micrograms (42.6 nmol) to 114.8 micrograms (177.8 nmol), but did not increase the ED50 values of either DELT or DAMGO. Increasing the dose of BNTX to 3 micrograms did not produce a significantly greater antagonism of the antinociceptive effects of DPDPE and did not antagonize the antinociceptive effects of DAMGO. However, it did enhance the antinociceptive effects of DELT decreasing its ED50 from 5.3 to 0.18 micrograms in the tail flick test. In the hot plate test, 10 min pretreatment with 1 microgram of BNTX selectively antagonized the antinociceptive effects of DPDPE, but did not antagonize the actions of DAMGO or DELT. Increasing the dose of BNTX to 3 micrograms also did not produce a significantly greater antagonism of the antinociceptive effects of DPDPE in the hot plate test, but did antagonize both the increase in hot plate latency and the modest decrement in motor function produced by 30 micrograms i.t. of DELT. However, the antagonism of these effects of DELT occurred much later in time than BNTX's antagonism of the antinociceptive effects of DPDPE.
authors.affiliation: Department of Anesthesia and Critical Care, University of Chicago, Illinois, USA.
authors.forename: D L
authors.initials: DL
authors.lastname: Hammond
authors.forename: P E
authors.initials: PE
authors.lastname: Stewart
authors.forename: L
authors.initials: L
authors.lastname: Littell
mesh_terms: D000700:Analgesics / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D001597:Benzylidene Compounds / Q000008:administration & dosage / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; D020881:Enkephalin, D-Penicillamine (2,5)-; D004745:Enkephalins / Q000494:pharmacology; D007278:Injections, Spinal; D008297:Male; D009271:Naltrexone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D009842:Oligopeptides / Q000494:pharmacology; D017288:Pain Threshold / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D017465:Receptors, Opioid, delta / Q000037:antagonists & inhibitors*; D013116:Spinal Cord / Q000187:drug effects* / Q000378:metabolism
chemical_list: D000700:Analgesics; D001597:Benzylidene Compounds; D004745:Enkephalins; D009292:Narcotic Antagonists; D009842:Oligopeptides; D017465:Receptors, Opioid, delta; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; C068868:naltrindole benzofuran; C060209:deltorphin II, Ala(2)-; C077358:7-benzylidenenaltrexone; D009271:Naltrexone; D020881:Enkephalin, D-Penicillamine (2,5)-